Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

The history of bendamustine

ASH 2010

Published: 28 Feb 2011

Views: 11558

Rating:

Save

Prof Mathias Rummel - Klinikum der Justus-Liebig-Universität, Giessen, Germany

Prof Mathias Rummel talks about the history of bendamustine from its origins in 1960’s East Germany to the modern trials evaluating the use of bendamustine and rituximab to treat lymphoproliferative diseases.

Related Videos

Relapsed Refractory Multiple Myeloma

Dr Hari Menon - St. Johns National Academy of Health Sciences, Bengaluru, India

$Relapsed Refractory Multiple Myeloma ( Dr Hari Menon - St. Johns National Academy of Health Sciences, Bengaluru, India )$

Multiple myeloma (A cancer arising from plasma cells)

Dr Nikesh Bajracharya - Civil Service Hospital, Kathmandu, Nepal

Multiple myeloma (A cancer arising from plasma cells) ( Dr Nikesh Bajracharya - Civil Service Hospital, Kathmandu, Nepal )

Epitope editing enables targeted immunotherapy of acute myeloid leukaemia

Dr Gabriele Casirati - Dana-Farber Cancer Institute, Boston, USA

Epitope editing enables targeted immunotherapy of acute myeloid leukaemia ( Dr Gabriele Casirati - Dana-Farber Cancer Institute, Boston, USA )

Hodgkin’s and non-Hodgkin’s lymphomas (NHL)

Dr Jose Sandoval Sus - Memorial Healthcare System, Florida, USA

Hodgkin’s and non-Hodgkin’s lymphomas (NHL) ( Dr Jose Sandoval Sus - Memorial Healthcare System, Florida, USA )

Real-world use of brexu-cel shows benefit in R/R mantle cell lymphoma treatment

Dr Nausheen Ahmed - The University of Kansas Cancer, Kansas, USA

Real-world use of brexu-cel shows benefit in R/R mantle cell lymphoma treatment ( Dr Nausheen Ahmed - The University of Kansas Cancer, Kansas, USA )

Venetoclax and ibrutinib therapy shows favourable results in the treatment of R...

Prof Arnon Kater - Amsterdam UMC, Amsterdam, Netherlands

Venetoclax and ibrutinib therapy shows favourable results in the treatment of R/R chronic lymphocytic leukaemia ( Prof Arnon Kater - Amsterdam UMC, Amsterdam, Netherlands )

Nivolumab-AVD reduces the risk of disease progression compared to brentuximab...

Dr Alex Herrera - City of Hope Comprehensive Cancer Center, Duarte, USA

Nivolumab-AVD reduces the risk of disease progression compared to brentuximab vedotin-AVD in advanced Hodgkin lymphoma ( Dr Alex Herrera - City of Hope Comprehensive Cancer Center, Duarte, USA )

Zanubrutinib demonstrates superior PFS compared with ibrutinib for treatment of...

Dr Mazyar Shadman - Fred Hutchinson Cancer Center, Seattle, USA

Zanubrutinib demonstrates superior PFS compared with ibrutinib for treatment of R/R CLL and SLL ( Dr Mazyar Shadman - Fred Hutchinson Cancer Center, Seattle, USA )

Effective treatment of low risk acute GVHD with itacitinib monotherapy

Prof Aaron Etra - The Tisch Cancer Institute, Mount Sinai, USA

Effective treatment of low risk acute GVHD with itacitinib monotherapy ( Prof Aaron Etra - The Tisch Cancer Institute, Mount Sinai, USA )

More from ecancer